Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales CAMBRIDGE, MA / ACCESS Newswire / January 29, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced a strategic collaboration with Recordati to advance Moderna's investigational propionic acidemia (PA) therapeutic, mRNA-3927, through the final stage ...